16401-14-2

Basic information

• Product Name: 5-FORMYLISOXAZOLE
• Synonyms: ISOXAZOLE-5-CARBALDEHYDE;5-ISOXAZOLECARBOXALDEHYDE;5-FORMYLISOXAZOLE;Isoxazole-5-carboxaldehyde;1,2-oxazole-5-carbaldehyde
• CAS NO: 16401-14-2
• Molecular Formula: C₄H₃NO₂
• Molecular Weight: 97.07
• Mol File: 16401-14-2.mol

Chemical Properties

• Boiling Point: 212℃
• Flash Point: 82℃
• Appearance: /
• Density: 1.258
• Vapor Pressure: 0.178mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.78±0.50(Predicted)
• CAS DataBase Reference: 5-FORMYLISOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-FORMYLISOXAZOLE(16401-14-2)
• EPA Substance Registry System: 5-FORMYLISOXAZOLE(16401-14-2)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 16401-14-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-FORMYLISOXAZOLE is used as a reagent for the synthesis of N-(benzo[1,2,3]triazol-1-yl)-N-((benzyl)acetamido)phenyl carboxamides, which are known as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors. These inhibitors play a crucial role in the development of antiviral drugs targeting SARS-CoV and related coronaviruses.
5-FORMYLISOXAZOLE is also used as a reagent in the synthesis of TC-6683, an α4β2 nicotinic acetylcholine receptor agonist. 5-FORMYLISOXAZOLE is being investigated for its potential in treating cognitive disorders, such as Alzheimer's disease and other forms of dementia, by modulating the neurotransmission in the brain.

InChI:InChI=1/C4H3NO2/c6-3-4-1-2-5-7-4/h1-3H

Upstream product

• 98019-60-4 5-(hydroxymethyl)isoxazole 
• 15055-81-9 methyl 1,2-oxazole-5-carboxylate 

Downstream Products

• 220779-47-5 (6R,7R)-3-((Z)-2-Isoxazol-5-yl-vinyl)-8-oxo-7-{2-[2-(trityl-amino)-thiazol-4-yl]-2-[(Z)-trityloxyimino]-acetylamino}-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 4-methoxy-benzyl ester 
• 1219004-75-7 (4S)-3-[(2S,3S)-2-(biphenyl-4-ylmethoxy)-3-hydroxy-2-methyl-3-(isoxazol-5-yl)propanoyl]-5,5-dimethyl-4-phenyl-1,3-oxazolidin-2-one 

Relevant articles and documents

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

INTEGRASE INHIBITORS 3

The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.

1-cyclopropyl-4-pyridyl-quinolinones

Compounds of formula STR1 wherein R1 is hydrogen, lower-alkyl, or trifluoromethyl; R2 is lower-alkyl, trifluoromethyl or CH2 Z where Z is hydroxy, chloro, lower-alkylamino or dilower-alkylamino; R3 and R4 are each individually hydrogen or fluoro; and Ar is phenyl, an aromatic 5- or 6-membered heterocycle or any of these substituted at one or more positions with lower-alkyl, fluoro, chloro, hydroxy, amino, lower-alkylamino, dilower-alkylamino, carboxy, sulfonamido, lower alkylsulfonamido, methylenedioxy, trifluoroacetamido, lower-alkanoylamino, or carbamoyl; and their pharmaceutically acceptable acid addition salts are useful as anticancer agents.